Premium
Clinical trial enrollment of adolescents and young adults with sarcoma
Author(s) -
Davis Lara E.,
Janeway Katherine A.,
Weiss Aaron R.,
Chen YenLin E.,
Scharschmidt Thomas J.,
Krailo Mark,
Glade Bender Julia L.,
Kopp Lisa M.,
Patel Shreyaskumar R.,
Schwartz Gary K.,
Horvath L. Elise,
Hawkins Douglas S.,
Chuk Meredith K.,
Reinke Denise K.,
Gorlick Richard G.,
Randall R. Lor
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30757
Subject(s) - medicine , sarcoma , clinical trial , pediatrics , gerontology , family medicine , pathology
More than half of all sarcomas occur in adolescents and young adults (AYAs) aged 15 to 39 years. After the publication of the AYA series in the April 1, 2016 issue of Cancer , several leaders in the field of sarcoma across disciplines gathered to discuss the status of sarcoma clinical research in AYAs. They determined that a focused effort to include the underrepresented and understudied AYA population in current and future sarcoma clinical trials is overdue. Trial enrichment for AYA‐aged sarcoma patients will produce more meaningful results that better represent the disease's biology, epidemiology, and treatment environment. To address the current deficit, this commentary outlines changes believed to be necessary to expediently achieve an increase in the enrollment of AYAs in sarcoma clinical trials. Cancer 2017;123:3434‐40 . © 2017 American Cancer Society .